Attenuated revertant serotype 1 marek's disease vaccine
AssigneeThe United States of America as represented by the Secretary of Agriculture
InventorRichard L. Witter
Life of this patent
Estimating the term…
Abstract
A Marek's disease vaccine comprising an attenuated revertant virus derived as a clone of Md11/75/R2 or an antigenic component of the virus is characterized by a markedly reduced pathogenicity compared to the parent virus, without a comparable loss in immunogenicity. Attenuated revertants of the invention are exemplified by Md11/75/R2/23 and Md11/75/R2/29. These viruses or immunogenic components thereof can be formulated into monovalent and polyvalent vaccines.
Claims6
A vaccine comprising:
- (1) a live attenuated revertant virus clone having all of the identifying characteristics of Md11/75C/R2/23 or Md11/75C/R2/29 in a dosage effective to elicit an immune response to a Marek's disease virus and (2) a pharmaceutically acceptable carrier or diluent.
A method for protecting a chicken against Marek's diseases comprising inoculating said chicken with a virus clone in a pharmaceutically acceptable carrier or diluent, wherein said virus clone is a live attenuated revertant virus clone having all of the identifying characteristics of Md11/75C/R2/23 or Md11/75C/R2/29 in a dosage effective to elicit an immune response to a Marek'disease virus.
Dependencies are inferred from the claim text.